Avenue Therapeutics Inc. (ATXI)
NASDAQ: ATXI
· Real-Time Price · USD
0.25
0.01 (5.00%)
At close: Apr 28, 2025, 10:00 AM
5.00% (1D)
| Bid | 0.23 |
| Market Cap | 774.83K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.15M |
| EPS (ttm) | -15.79 |
| PE Ratio (ttm) | -0.02 |
| Forward PE | -0.13 |
| Analyst | n/a |
| Ask | 0.26 |
| Volume | 106 |
| Avg. Volume (20D) | 74,004 |
| Open | 0.25 |
| Previous Close | 0.24 |
| Day's Range | 0.25 - 0.25 |
| 52-Week Range | 0.23 - 5.97 |
| Beta | 0.10 |
About ATXI
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York....
Industry Biotechnology
Sector Healthcare
IPO Date Jun 27, 2017
Employees 2
Stock Exchange NASDAQ
Ticker Symbol ATXI
Website https://www.avenuetx.com
